NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) Stock Analysis - Analyst Ratings

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a publicly traded Healthcare sector company. As of May 20, 2026, NAMS trades at $35.77 with a market cap of $3.99B and a P/E ratio of -20.07. NAMS moved +6.11% today. Year to date, NAMS is +6.78%; over the trailing twelve months it is +84.75%. Its 52-week range spans $14.06 to $42.21. Analyst consensus is strong buy with an average price target of $48.00. Rallies surfaces NAMS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate NAMS?

11 analysts cover NAMS: 0 strong buy, 10 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $48.00.

NAMS Key Metrics

Key financial metrics for NAMS
MetricValue
Price$35.77
Market Cap$3.99B
P/E Ratio-20.07
EPS$-1.79
Dividend Yield0.00%
52-Week High$42.21
52-Week Low$14.06
Volume1.15M
Avg Volume0
Revenue (TTM)$22.57M
Net Income$-212.73M
Gross Margin0.00%

NAMS Analyst Consensus

11 analysts cover NAMS: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.00.

Latest NAMS News

Recent NAMS Insider Trades

  • LANGE LOUIS G sold 44.17K (~$1.34M) on Mar 11, 2026.
  • LANGE LOUIS G sold 446 (~$13.93K) on Mar 11, 2026.
  • Kastelein Johannes Jacob Pieter sold 101.41K (~$3.07M) on Mar 9, 2026.

Common questions about NAMS

What do analysts rate NAMS?
11 analysts cover NAMS: 0 strong buy, 10 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $48.00.
Does Rallies show NAMS price targets?
Yes. Rallies tracks NAMS analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is NAMS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NAMS. It does not provide personalized investment advice.
NAMS

NAMS